1. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema.
Ophthalmology 2002;109:920-927.
2. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.
Ophthalmology 2001;108:765-772.
3. Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
Br J Ophthalmol 2002;86:247-248.
4. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.
Retina 2000;20:244-250.
5. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.
Am J Ophthalmol 2001;132:425-427.
6. Jonas JB, Sofker A. Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularization.
J Cataract Refract Surg 2002;28:2040-2041.
7. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.
Am J Ophthalmol 2001;131:468-471.
8. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.
J Glaucoma 2001;10:284-287.
9. Rubsamen PE, Cousins SW. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy.
Retina 1997;17:44-50.
10. Rubsamen PE, Davis PA, Hernandez E, et al. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil.
Arch Ophthalmol 1994;112:407-413.
11. Berger AS, Cheng CK, Pearson PA, et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
Invest Ophthalmol Vis Sci 1996;37:2318-2325.
12. Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.
Arch Ophthalmol 1998;116:69-77.
13. Ando N, Sen HA, Berkowitz BA, et al. Localization and quantitation of blood-retinal barrier breakdown in experimental proliferative vitreoretinopathy.
Arch Ophthalmol 1994;112:117-122.
14. Faghihi H, Taheri A, Farahvash MS, et al. Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial.
Retina 2008;28:1241-1246.
15. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic vitreous hemorrhage.
Arch Ophthalmol 1987;105:191-195.
16. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy.
Ophthalmology 2007;114:710-715.
17. Farrahi F, Feghhi M, Bagherzadeh B, Latifi M. Sulfur hexafluoride 20% versus lactated ringer's solution for prevention of early postoperative vitreous hemorrhage after diabetic vitrectomy.
J Ophthalmic Vis Res 2010;5:105-109.
18. The classification of retinal detachment with proliferative vitreoretinopathy.
Ophthalmology 1983;90:121-125.
19. Ahmadieh H, Feghhi M, Tabatabaei H, et al. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial.
Ophthalmology 2008;115:1938-1943.
20. Cheema RA, Peyman GA, Fang T, et al. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy.
Ophthalmic Surg Lasers Imaging 2007;38:365-370.
21. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Can J Ophthalmol 2005;40:598-604.
22. Verma LK, Vivek MB, Kumar A, et al. A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema.
J Ocul Pharmacol Ther 2004;20:277-284.
23. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis.
Am J Ophthalmol 1995;120:55-64.
24. Jonas JB, Sofker A, Degenring R. Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy.
Eur J Ophthalmol 2003;13:468-473.
25. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown.
Graefes Arch Clin Exp Ophthalmol 2002;240:423-429.
26. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.
Prog Retin Eye Res 2005;24:587-611.
27. Croasdale CR, Brightbill FS. Subconjunctival corticosteroid injections for nonnecrotizing anterior scleritis.
Arch Ophthalmol 1999;117:966-968.
28. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide.
Ophthalmology 1996;103:2099-2104.
29. Floman N, Zor U. Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production.
Invest Ophthalmol Vis Sci 1977;16:69-73.
30. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation.
Arch Ophthalmol 1992;110:1155-1159.
31. Hood PP, Cotter TP, Costello JF, Sampson AP. Effect of intravenous corticosteroid on ex vivo leukotriene generation by blood leucocytes of normal and asthmatic patients.
Thorax 1999;54:1075-1082.
32. Ozaki NK, Beharry KD, Nishihara KC, et al. Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia.
Invest Ophthalmol Vis Sci 2002;43:1546-1557.
33. Lafranco Dafflon M, Tran VT, Guex-Crosier Y, Herbort CP. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects.
Graefes Arch Clin Exp Ophthalmol 1999;237:289-295.
34. Shen L, You Y, Sun S, et al. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application.
Ophthalmology 2010;117:2365-2371.
35. Entezari M, Ahmadieh H, Dehghan MH, et al. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial.
Eur J Ophthalmol 2005;15:746-750.
36. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure.
Am J Ophthalmol 2004;138:740-743.
37. Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract.
Ophthalmology 2005;112:139-143.
38. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection.
Ophthalmology 2005;112:593-598.
39. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide.
Br J Ophthalmol 2003;87:24-27.
40. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial.
Arch Ophthalmol 2004;122:336-340.
41. Mueller AJ, Jian G, Banker AS, et al. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure.
Am J Ophthalmol 1998;125:158-163.